Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Renato Ceravolo"'
1
Cardio-Toxicity during chemotherapy: feasibility of new diagnostic approaches
Autor: Fable Zustovich, Rosanna Canton, Renato Ceravolo, Martina Zaninotto, Mario Trivellato, Monica Maria Mion, Mario Plebani, Giuseppe Cartei, Martina Mattiazzi, Davide Pastorelli, Lorena Buratin
Publikováno v: Health. :376-380
Chemotherapy induced cardio-toxicity is a well known side effect of anticancer treatments, moreover the 70% of all tumors involve patients over 65 years-old, frequently with cardiac co- morbidity. We evaluated the feasibility of the application durin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a9d35346991500ab0f5dd48e30b3fa90
https://doi.org/10.4236/health.2010.24056
Zobrazit plný text záznamu
3
The New Reticulocyte Parameter (RET-Y) of the Sysmex XE 2100
Autor: Renato Ceravolo, Valeria Temporin, Giorgio Farina, Pietro Bulian, Mauro Buttarello
Publikováno v: American Journal of Clinical Pathology. 121:489-495
To verify their clinical usefulness in diagnosis and early response to therapy of sideropenic anemia, we compared the behavior of the reticulocyte parameter (RET-Y), a raw measure dependent on size and content of the cell, generated by the Sysmex XE
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ee1491df1c4b7edb6278c1289e79d3e
https://doi.org/10.1309/w65295dtuwk7u1hh
Zobrazit plný text záznamu
4
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma
Autor: Lara Furini, Davide Pastorelli, Stefania Zovato, Giovanni Faggioni, Martin Donach, Miriam Farina, Renato Ceravolo, Fable Zustovich, Paolo Carli, Giuseppe Lombardi, Ornella Nicoletto
Publikováno v: Anti-cancer drugs. 21(2)
In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizuma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075aaab69a15d5e55c9df286aedd9f8d
https://pubmed.ncbi.nlm.nih.gov/19952729
Zobrazit plný text záznamu
5
A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors
Autor: Fable, Zustovich, Giuseppe, Cartei, Renato, Ceravolo, Stefania, Zovato, Alessandro, Della Puppa, Davide, Pastorelli, Martina, Mattiazzi, Roberta, Bertorelle, Marina Paola, Gardiman
Publikováno v: Anticancer research. 27(2)
There is pre-clinical evidence of synergism between cisplatin (P) and temozolomide (T) due to higher inhibition by T of O6-alkyl-guanine-alkyltransferase (AGAT), an enzyme involved in the mismatch repair system. T and P are active against malignant g
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6490e9086723d5578cfdd4832acc2025
https://pubmed.ncbi.nlm.nih.gov/17465237
Zobrazit plný text záznamu
6
Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy
Autor: A. Iop, Samuela Binato, E. Colombrino, U. Fantoni, S. Cingarlini, Cosimo Sacco, Giuseppe Cartei, A. Palamidese, Simona Scalone, Renato Ceravolo, Alessandra Bearz
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 17
Chemotherapy of non-small-cell lung cancer (NSCLC) has been improved by the use of cis-platin (P) and the pyrimidine antimetabolite gemcitabine (G) (2',2'-difluorodeoxycytidine). GP regimens currently used in Italy for NSCLC were and are mainly based
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c1e7c6547f9317c2ad376e37cc4cb59
https://pubmed.ncbi.nlm.nih.gov/16807462
Zobrazit plný text záznamu
7
The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia
Autor: Mauro, Buttarello, Valeria, Temporin, Renato, Ceravolo, Giorgio, Farina, Pietro, Bulian
Publikováno v: American journal of clinical pathology. 121(4)
To verify their clinical usefulness in diagnosis and early response to therapy of sideropenic anemia, we compared the behavior of the reticulocyte parameter (RET-Y), a raw measure dependent on size and content of the cell, generated by the Sysmex XE
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::293e98b4cd50d2341fdb35a6f66c394d
https://pubmed.ncbi.nlm.nih.gov/15080300
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje